## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	ırden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe steep essee.	-,													
1. Name and Address of Reporting Person * LYONS GARY A				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner				
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/17/2018						-	Officer (give	e title below)	Other	(specify below)	
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Deri	vative Securitie	s Acquir	ed, Disposed	of, or Bene	ficially Owned	ı	
1.Title of S (Instr. 3)	Date			2A. Deemed Execution Date r) any (Month/Day/Y		ate, if Code (Instr.		8) (1	. Securities Acq A) or Disposed of Instr. 3, 4 and 5)	of (D) Owned Follow			d OF	vnership of rm: Be	eneficial wnership
Reminder:	Report on a s	separate fine for each	i class of securities	ochenera	ily Ow.	nea ane	otiy .			d to the	collection	of informat	tion contains	d SEC 14	74 (9-02)
Reminder:	Report on a s	separate fine for each		· Derivati	ive Sec	curities	Acq	Person in this display uired, Dispo	s who respon form are not r is a currently osed of, or Bend	equired valid ON	to respond IB control r	unless the		d SEC 14	74 (9-02)
1. Title of	2. Conversion	3. Transaction	Table II -  3A. Deemed Execution Date, if	Derivati (e.g., pu 4. Transac Code	ive Sects, call  5 tion of S  Office of S  O	curities ls, warr	Acq eants, er ative es d (A) sed	Person in this display uired, Dispose, options, co	s who respon form are not r is a currently osed of, or Bend nvertible secur crecisable and Date	equired valid ON eficially Control	to respond  IB control r  Owned  and Amount rlying es	unless the umber.	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indired Beneficia
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II -  3A. Deemed Execution Date, if any	Derivati (e.g., pu 4. Transac Code	ive Sects, call  5 tion of S  Office of S  O	curities ls, warr . Numb of Deriva securitie Acquirec or Dispon of (D) Instr. 3, nd 5)	Acq eants, er ative es d (A) sed	Person in this display uired, Dispose, options, co	s who respon form are not r s a currently osed of, or Bene nvertible secur creisable and Date y/Year)	equired valid ON eficially Cities)  7. Title a of Under Securities	to respond  IB control r  Owned  and Amount rlying es	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownersh

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
LYONS GARY A C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

#### **Signatures**

/s/Dolly Vance (Attorney-in-Fact)	05/18/2018
Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares shall vest monthly over one (1) years from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.